Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Genprex. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Genprex's earnings available for a low price, and how does
this compare to other companies in the same industry?
Genprex's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Genprex is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Genprex's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. John Rodney Varner is a co-founder of Genprex, Inc. and has been the Chief Executive Officer, Secretary and Chairman of the Board of Genprex, Inc. since August 2012. He served as President at Genprex, Inc. since August 2012 until April 10, 2018. Mr. Varner has more than thirty-three years of legal experience with large and small law firms and as outside general counsel of a NASDAQ traded company. He represents for-profit and non-profit companies at the Board of Directors or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues and real estate matters. He serves as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for Fifth Circuit and the United States Tax Court. He is a registered securities representative and owner of a company that is a licensed securities broker-dealer. He maintains Series 7, 24, 63 and 79 securities registrations. He is a member of the Board of Directors of Texas Healthcare and Bioscience Institute (THBI), and serves as its General Counsel. He is also a founder and member of the Board of Directors of Texas Medical Device Alliance. He holds J.D. from University of Texas School of Law in 1978 and holds BBA with high honors from Texas A & M University in 1976.
John's compensation has been consistent with company performance over the past year.
John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Genprex management team is about average.
President & COO
Chief Financial Officer
Chairman of Scientific & Medical Advisory Board
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Genprex board of directors is about average.
Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.